NASDAQ:CLRB - Cellectar Biosciences News Headlines

Sign in or create an account to add this stock to your watchlist.
$1.86 -0.14 (-7.00 %)
(As of 05/20/2019 04:00 PM ET)
Previous Close$2.00
Today's Range$1.78 - $2.00
52-Week Range$1.22 - $12.76
Volume402,187 shs
Average Volume1.04 million shs
Market Capitalization$9.49 million
P/E RatioN/A
Dividend YieldN/A
Beta1.22

Headlines

Cellectar Biosciences (NASDAQ CLRB) News Headlines

Source:
DateHeadline
5 Biotech Stocks to Watch in the Second Half of 20195 Biotech Stocks to Watch in the Second Half of 2019
finance.yahoo.com - May 20 at 12:32 PM
Cellectar down 25% on $10M capital raiseCellectar down 25% on $10M capital raise
seekingalpha.com - May 16 at 11:03 AM
Cellectar Biosciences Announces $10.0 Million FinancingCellectar Biosciences Announces $10.0 Million Financing
finance.yahoo.com - May 16 at 11:03 AM
Cellectar up 31% on more positive CLR 131 dataCellectar up 31% on more positive CLR 131 data
seekingalpha.com - May 15 at 6:46 PM
CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple MyelomaCLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma
finance.yahoo.com - May 15 at 9:35 AM
-$0.60 EPS Expected for Cellectar Biosciences Inc (CLRB) This Quarter-$0.60 EPS Expected for Cellectar Biosciences Inc (CLRB) This Quarter
www.americanbankingnews.com - May 14 at 6:34 PM
Cellectars CLR 131 Fast Trackd for multiple myeloma; shares up 6%Cellectar's CLR 131 Fast Track'd for multiple myeloma; shares up 6%
seekingalpha.com - May 13 at 6:41 PM
Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple MyelomaCellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma
finance.yahoo.com - May 13 at 9:35 AM
Cellectar Biosciences (CLRB) Issues Quarterly  Earnings ResultsCellectar Biosciences (CLRB) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 7 at 7:49 AM
Cellectar Reports First Quarter 2019 Financial Results and Provides a Corporate UpdateCellectar Reports First Quarter 2019 Financial Results and Provides a Corporate Update
finance.yahoo.com - May 6 at 9:35 AM
Cellectar Biosciences (CLRB) Earns Buy Rating from Analysts at HC WainwrightCellectar Biosciences (CLRB) Earns Buy Rating from Analysts at HC Wainwright
www.americanbankingnews.com - May 2 at 12:05 PM
Cellectar Biosciences, Inc. (NASDAQ:CLRB): Are Analysts Right About The Drop In Earnings?Cellectar Biosciences, Inc. (NASDAQ:CLRB): Are Analysts Right About The Drop In Earnings?
finance.yahoo.com - April 29 at 5:46 PM
U.S. STOCKS ON THE MOVE-Weed Stocks, Revlon, Shineco - NasdaqU.S. STOCKS ON THE MOVE-Weed Stocks, Revlon, Shineco - Nasdaq
www.nasdaq.com - March 20 at 9:18 AM
Cellectar Biosciences Inc.Cellectar Biosciences Inc.
www.barrons.com - March 19 at 6:26 PM
Cellectar Bio up 40% premarket on advancement of CLR 131Cellectar Bio up 40% premarket on advancement of CLR 131
seekingalpha.com - March 19 at 6:26 PM
FDA Grants Exemption to Import Alert for Cellectar’s CLR 131 in Pediatric and Adolescent PatientsFDA Grants Exemption to Import Alert for Cellectar’s CLR 131 in Pediatric and Adolescent Patients
finance.yahoo.com - March 19 at 9:51 AM
Cellectar Biosciences, Inc. Estimate MomentumCellectar Biosciences, Inc. Estimate Momentum
www.nasdaq.com - March 18 at 6:32 PM
Cellectar Biosciences IncCellectar Biosciences Inc
www.bloomberg.com - March 18 at 6:32 PM
Cellectar Reports Financial Results for Year Ended December 31, 2018 and Provides a Corporate UpdateCellectar Reports Financial Results for Year Ended December 31, 2018 and Provides a Corporate Update
finance.yahoo.com - February 26 at 9:59 AM
Cellectar Bio up 7% on positive CLR 131 dataCellectar Bio up 7% on positive CLR 131 data
seekingalpha.com - February 25 at 6:06 PM
Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131
finance.yahoo.com - February 25 at 10:34 AM
Cellectar Biosciences to Present at the Annual BIO CEO & Investor ConferenceCellectar Biosciences to Present at the Annual BIO CEO & Investor Conference
finance.yahoo.com - February 5 at 5:27 PM
Cellectar Biosciences to Present at NobleConXV, Noble Capital Markets’ Fifteenth Annual Investor ConferenceCellectar Biosciences to Present at NobleConXV, Noble Capital Markets’ Fifteenth Annual Investor Conference
finance.yahoo.com - January 23 at 9:21 AM
What Kind Of Shareholders Own Cellectar Biosciences, Inc. (NASDAQ:CLRB)?What Kind Of Shareholders Own Cellectar Biosciences, Inc. (NASDAQ:CLRB)?
finance.yahoo.com - January 22 at 5:27 PM
Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple MyelomaCellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma
finance.yahoo.com - January 7 at 9:20 AM
Cellectar Biosciences to Present at the Biotech ShowcaseCellectar Biosciences to Present at the Biotech Showcase
finance.yahoo.com - January 3 at 9:38 AM
Cellectar Granted Japanese Patent for CLR 131 Nasdaq:CLRB - GlobeNewswireCellectar Granted Japanese Patent for CLR 131 Nasdaq:CLRB - GlobeNewswire
globenewswire.com - December 12 at 4:53 PM
Cellectar Biosciences (CLRB) Secures Patent in Japan for CLR 131 - StreetInsider.comCellectar Biosciences (CLRB) Secures Patent in Japan for CLR 131 - StreetInsider.com
www.streetinsider.com - December 12 at 4:53 PM
Cellectar Granted Japanese Patent for CLR 131Cellectar Granted Japanese Patent for CLR 131
finance.yahoo.com - December 11 at 10:05 AM
Cellectar Biosciences (CLRB) Commences Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple MyelomaCellectar Biosciences (CLRB) Commences Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma
www.streetinsider.com - December 5 at 4:33 PM
Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple MyelomaCellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma
finance.yahoo.com - December 4 at 9:33 AM
Cellectar Reports Third Quarter 2018 Financial Results and Provides Business UpdateCellectar Reports Third Quarter 2018 Financial Results and Provides Business Update
finance.yahoo.com - November 13 at 9:03 AM
BRIEF-Cellectar Announces FDA Grants Exemption To Import Alert For CLR 131 Hematology StudiesBRIEF-Cellectar Announces FDA Grants Exemption To Import Alert For CLR 131 Hematology Studies
www.msn.com - November 12 at 4:31 PM
FDA grants exemption to Cellectar to import alert for CLR 131 hematology studiesFDA grants exemption to Cellectar to import alert for CLR 131 hematology studies
seekingalpha.com - November 12 at 4:31 PM
Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology StudiesCellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies
finance.yahoo.com - November 12 at 9:07 AM
Cellectar Bio CLR 131 shows positive action in early-stage multiple myeloma study; shares ahead 43% premarketCellectar Bio CLR 131 shows positive action in early-stage multiple myeloma study; shares ahead 43% premarket
seekingalpha.com - October 2 at 4:17 PM
Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple MyelomaCellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma
finance.yahoo.com - October 2 at 9:12 AM
Todays Research Reports on Trending Tickers: Onconova Therapeutics and Cellectar BiosciencesToday's Research Reports on Trending Tickers: Onconova Therapeutics and Cellectar Biosciences
finance.yahoo.com - September 27 at 9:22 AM
Cellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare ConferenceCellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare Conference
finance.yahoo.com - September 27 at 9:22 AM
Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric OsteosarcomaCellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma
finance.yahoo.com - September 25 at 9:21 AM
Cellectar Biosciences Provides an Update on the FDA Import AlertCellectar Biosciences Provides an Update on the FDA Import Alert
finance.yahoo.com - September 24 at 9:27 AM
Cellectar Biosciences (CLRB) Says FDA Granted Rare Pediatric Disease Designation to its CLR 131 for Treatment of OsteosarcomaCellectar Biosciences (CLRB) Says FDA Granted Rare Pediatric Disease Designation to its CLR 131 for Treatment of Osteosarcoma
www.streetinsider.com - September 18 at 9:29 AM
Cellectar Bio up 24% premarket on another RPDD tag for CLR 131Cellectar Bio up 24% premarket on another RPDD tag for CLR 131
seekingalpha.com - September 17 at 4:30 PM
Cellectar stock surges 15% premarket after FDA fast tracks treatment for rare childhood cancerCellectar stock surges 15% premarket after FDA fast tracks treatment for rare childhood cancer
www.marketwatch.com - September 17 at 9:10 AM
FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences CLR 131 for the Treatment of OsteosarcomaFDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences' CLR 131 for the Treatment of Osteosarcoma
www.marketwatch.com - September 17 at 9:10 AM
FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of OsteosarcomaFDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma
finance.yahoo.com - September 17 at 9:10 AM
Form 8-K Cellectar Biosciences, For: Sep 06Form 8-K Cellectar Biosciences, For: Sep 06
www.streetinsider.com - September 6 at 9:47 AM
Cellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment ConferenceCellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
finance.yahoo.com - August 29 at 9:43 AM
Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma PatientsFractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma Patients
finance.yahoo.com - August 20 at 9:41 AM
Cellectars CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewings SarcomaCellectar's CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing's Sarcoma
globenewswire.com - August 15 at 9:35 AM
This page was last updated on 5/20/2019 by MarketBeat.com Staff

Featured Article: Depreciation

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel